




From Legacy to Leading Edge in MPN Care and Research

Presidents:

Alessandro Lucchesi
Gerardo Musuraca

Scientific Secretariat:

Alessandro Lucchesi
Monica Poggiaspalla
Francesco Malaspina
Claudio Cerchione
Maria Benedetta Giannini
Federica Frabetti
Selene Guerzoni
Giorgia Micucci

Honorary President:

Nicola Normanno

RISE
MPN

2025

Rome

7/8 november

The Hive Hotel
Via Torino, 6



Rationale

RiseMPN 2025 marks a turning point in the evolving landscape of myeloproliferative neoplasms. With the first wave of results from pivotal phase 3 trials now available, the time has come to critically reassess our therapeutic paradigms and embrace innovation.

This year's congress invites participants to explore the frontiers of inflammation, innate immunity, and fibrotic progression as central pillars of MPN pathogenesis and transformation. The programme highlights cutting-edge translational science, risk-adapted therapeutic strategies, and molecular classification, while also revisiting the evolving role of allogeneic transplantation in the era of targeted therapies.


Special sessions will explore augmented intelligence and real-world data, the impact of MPNs on life milestones such as pregnancy and adolescence, and the relevance of rare myeloid neoplasms including mastocytosis and hypereosinophilic syndromes.

RiseMPN 2025 reaffirms its mission as a collaborative, European stage for scientific dialogue, translational breakthroughs, and clinical evolution - where bold ideas meet clinical precision, and the future of MPN care is shaped collectively.

Faculty

Alessandro Lucchesi Meldola
Gerardo Musuraca Meldola
Jean-Jacques Kiladjian Paris, France
Antonella Barone Rome
Claudio Franceschi Bologna
Elena Masselli Parma
Elena Rossi Rome
Thomas Fischer Magdeburg, Germany
Francisca Ferrer-Marin Murcia, Spain
Sebastiano Giallongo Enna
Jennifer O'Sullivan Oxford, UK
Daniela Cilloni Turin
Giorgia Micucci Meldola
Guglielmo Mariani London, UK
Thomas Renné Hamburg, Germany
Mariasanta Napolitano Palermo
Claudio Cerchione Meldola
Giulio Giordano Campobasso
Domenico Girelli Verona
Srinivas K. Tantravahi Salt Lake City, USA
Pankit Vachhani Birmingham, USA
Elena Crisà Candiolo
Marina Kremyanskaya New York, USA

Giovanni Caocci Cagliari
Giuseppe Antonio Palumbo Catania
Haifa Kathrin Al-Ali Halle, Germany
Michael Loschi Marseille, France
Carmen Fava Turin
Elisabetta Abruzzese Rome
Giovanni Martinelli Bologna
Monica Poggiaspalla Meldola
Andrea Patriarca Novara
Robert Kralovics Vienna, Austria
Daniele Cattaneo Milan
Selene Guerzoni Meldola
Enrico Maffini Bologna
Juan C. Hernández-Boluda Valencia, Spain
Patrizia Chiusolo Rome
Francesco Saraceni Ancona
Alice Andalò Meldola
Fabio Gori The Hague, The Netherlands
Nicola Normanno Meldola
Federica Frabetti Meldola
Marta Sobas Wroclaw, Poland
Novella Pugliese Naples
Thomas Münzel Mainz, Germany



RISE
MPN

09:30 - 10:05 Institutional Greetings

Welcome from the Scientific Committee, Local Authorities, and Patient Representatives

09:30 **A. Lucchesi** and **G. Musuraca**, Rise MPN Congress Presidents

09:35 EuroBloodNet Representative

09:45 **A. Barone**, President of AIPAMM

09:55 **Sen. Y. Zambito**, Government Representative, Intergroup on Rare Diseases

10:05 - 10:25 Opening Lecture

Chair: **E. Masselli**, **E. Rossi**

C. Franceschi - Immune Aging, Inflammaging and the metabolic cost of clonal survival

10:30 - 11:15 SESSION 1 The Fire Within: Inflammation as a Compass in MPN Pathogenesis

Chair: **J. O'Sullivan**, **D. Cilloni**

10:30 **T. Fischer** - Inflammation and clonal persistence: from signals to stem cells

10:45 **F. Ferrer-Marin** - NF-κB inhibition reduces and prevents the inflammation-driven myelofibrosis

11:00 **S. Giallongo** - Lactate as a key regulator of immune escape and BM fibrotic - transformation in MF

11:15 Open Discussion

11:30 - 11:45 Coffee Break

11:45 - 12:45 SESSION 2 Blood and Flame: Thrombosis and Thromboinflammation in MPNs

Chair: **G. Micucci**, **G. Mariani**

11:45 **T. Renné** - NETosis and Thrombo-inflammation in MPNs: Unravelling a Dangerous Liaison

12:00 **A. Lucchesi** - Thromboinflammation Beyond the Veins: Atherosclerosis and MPNs

12:15 **M. Napolitano** - Beyond DVT: Atypical Site Thrombosis in MPNs and Diagnostic Pitfalls

12:30 Open Discussion

12:45 - 13:30 SESSION 3 Between Blood and Bone: A Philosophical View on Anemia and Polyglobulia in MPNs

Chair: **C. Cerchione**

12:45 **G. Giordano** - Anemia in MPNs: A Clinical, Historical and Molecular Journey

13:05 **D. Girelli** - The Polyglobulic Puzzle: Iron, Inflammation and the Modern Diagnostic Challenge

13:25 Open Discussion

13:30 - 14:30 Light Lunch Break

14:30 - 15:45 SESSION 4 Balancing the Blood: Strategies in Anemia and Hematocrit Control

Chair: **S. K. Tantravahi, P. Vachhani**

- 14:30 **E. Crisà** - Managing Anemia in Myelofibrosis: Current Challenges and Emerging Solutions
- 14:45 **M. Kremyanskaya** - Hematocrit Control and Iron Metabolism Modulation in PV
- 15:00 **J. J. Kiladjian** - Interferons and Epigenetic Modifiers: Redefining the Therapeutic Landscape in PV
- 15:15 **G. Caocci** - Patient-Reported Outcomes in Anemia and PV Control: Measuring What Matters
- 15:30 Open Discussion

15:45 - 17:20 SESSION 5 Changing the Game: Phase 3 Trials Shaping the Future of MPN Therapy

Chair: **M. Kremyanskaya, A. Lucchesi**

- 15:45 **G. A. Palumbo** - From Revolution to Plateau: What 10 Years of JAK Inhibition Have Taught Us in MF and PV
- 16:15 **H. K. Al-Ali** - JAK Inhibition 2.0: Evolving Strategies for Cytopenic and Symptomatic Patients
- 16:30 **M. Loschi** - Rewriting Transcription: BET Inhibition and Selinexor
- 16:45 **P. Vachhani** - Pro-apoptotic Strategies in MPNs: MDM2 Inhibition and Telomerase Blockade
- 17:00 Panel Discussion: The Future of Therapeutic Algorithms in MPNs

17:20 - 17:35 The Rise Ritual: Evening Reflections & Networking Pause

A signature RiseMPN moment to pause, connect, and plant the seeds of tomorrow's ideas. Guests will be offered a symbolic glass of red wine or grape juice - "A Sip of Insight" - paired with a single square of dark chocolate. Each attendee will also receive a "Rise Note" card featuring a quote of the year and space to capture a thought, question, or inspiration for the future.

17:35 - 18:20 SESSION 6 CML Beyond Control: Navigating Chronic Myeloid Leukemia in 2025

Chair: **C. Fava**

- 17:35 **E. Abruzzese** - Dose Downgrading and Optimization in CML: Balancing Control and Quality of Life
- 17:50 **S. K. Tantravahi** - Managing Resistance and Late-Line Therapy: What's Next?
- 18:05 Open Discussion

18:15 - 19:15 SESSION 7 Rare but Relevant: Hypereosinophilic Syndromes and Mastocytosis

Chair: **G. Martinelli, M. Poggiaspalla**

- 18:15 **C. Fava** - Molecular Diagnostics in Rare MPNs
- 18:30 **D. Cilloni** - Advanced Systemic Mastocytosis
- 18:45 **A. Patriarca** - HES: Classification and Treatment
- 19:00 Open Discussion

08:40 - 09:20 Special Lectures

Chair: **E. Masselli, E. Rossi**

08:40 **G. Martinelli** - Metabolomic Signatures and Disease Trajectories in Myeloid Neoplasms

09:00 **T. Munzel** - From Air to Blood: How Environmental Stressors Shape Cardiovascular Risk

09:20 - 10:25 SESSION 8 Targeting the Roots: Novel Molecules and Immunotherapy in MF

Chair: **G. Musuraca, H. K. Al-Ali**

09:20 **J. O'Sullivan** - Novel Pathway Inhibitors in MF: Beyond JAK

09:35 **R. Kralovics** - Calreticulin as a Target: Immunobiology and the Therapeutic Rationale

09:50 **D. Cattaneo** - Monoclonal and Bispecific Antibodies Targeting Mutant CALR

10:05 Panel Discussion

10:25 - 11:40 SESSION 9 Still the Cure? Reassessing the Role of Allogeneic Transplantation

Chair: **P. Chiusolo, S. Guerzoni**

10:25 **E. Maffini** - The Delicate Dance: Who, When, and How to Bridge to Transplant in MF

10:40 **J. C. Hernández-Boluda** - From Burden to Bridge: Splenomegaly Management and Engraftment Improvement in MF Transplantation

10:55 **P. Chiusolo** - Clearing the Driver: Molecular Remission and Mutation Clearance Post-Transplant

11:10 **F. Saraceni** - How Old is Too Old? Rethinking Age Limits in Transplantation for Myeloid Neoplasms

11:25 Open Discussion

11:40–11:55 Coffee Break

11:55–12:35 SESSION 10 Augmented Intelligence: AI's Role in MPN Diagnosis and Therapy

Chair: **A. Andalò, A. Lucchesi**

11:55 **F. Gori** - Mathematical Intelligence in MPNs: Pattern Recognition and Predictive Insight

12:15 **A. Lucchesi** - From Insight to Impact: Making AI Work for Clinicians in MPN Care

12:25 Open Discussion

12:35 - 13:20 SESSION 11 Life Milestones and MPNs

Chair: **G. Caocci, F. Frabetti**

12:35 **M. Sobas** – MPNs in Adolescents and Young Adults

12:50 **N. Pugliese** – Pregnancy and MPNs

13:05 Open Discussion

13:20 - 13:50 Poster Walk and Award Ceremony

Best Poster Award presented by the RiseMPN Scientific Committee

13:50 - 14:00 Closing Remarks and RiseMPN 2026 Preview

With the Scientific Committee and Guests

14:00 Farewell Buffet Lunch

A final opportunity to network and reflect together before parting ways.

Informazioni

Il Convegno n. **5090-462007** è stato accreditato su **AGENAS** per **100 partecipanti**.

Professione	MEDICO CHIRURGO; FARMACISTA; TECNICO SANITARIO LABORATORIO BIOMEDICO;
Discipline	EMATOLOGIA; GENETICA MEDICA; MALATTIE INFETTIVE; MEDICINA INTERNA; ANATOMIA PATOLOGICA; FARMACOLOGIA E TOSSICOLOGIA CLINICA; MEDICINA TRASFUSIONALE; PATOLOGIA CLINICA (LABORATORIO DI ANALISI CHIMICO-CLINICHE E MICROBIOLOGIA); FARMACISTA PUBBLICO DEL SSN; FARMACISTA TERRITORIALE; FARMACISTA DI ALTRO SETTORE; INFERMIERE; TECNICO SANITARIO LABORATORIO BIOMEDICO; ISCRITTO NELL'ELENCO SPECIALE AD ESAURIMENTO;
Tipologia	CORSO DI AGGIORNAMENTO
Obiettivo	LINEE GUIDA - PROTOCOLLI - PROCEDURE CORSO GRATUITO

METODO D'ISCRIZIONE

Ai fini dell'ottenimento dei crediti ECM è necessario registrarsi sulla piattaforma **<https://didattica.xeniaeventi.it>**, iscriversi al corso di riferimento e compilare:


- Il questionario di apprendimento online (doppia randomizzazione e nessuna possibilità di ripetizione) dalle ore 20:00 del 07/11/2025. L'ultimo giorno utile per la compilazione è il 10/11/2025 alle ore 23:59.
- La scheda di valutazione in formato anonimo.

Nella propria sezione è possibile scaricare l'attestato ECM. Il rilascio dei crediti ECM è subordinato all'attenta verifica della partecipazione (90% delle ore formative) e del questionario di valutazione (superato con almeno il 75% di risposte corrette).



Crediti ECM
13,0

Promosso da:



**SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA**

**Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Istituto di Ricovero e Cura a Carattere Scientifico**

ISTITUT
ROMAGN
PER LO
DEI TUM
DINO AMADORI

Con il patrocinio di:



SIE



L'iniziativa è stata realizzata grazie al supporto incondizionato di:

gold



silver



supporting
sponsor



altro

